We have applied the method of genomic microarray to investigate amplification of oncogenes throughout the genome of nasopharyngeal carcinoma (NPC). Array based comparative genomic hybridization (array CGH) allows simultaneous examination of 58 oncogenes commonly amplified in various human cancers. In the present study, we have examined 15 NPC samples including five cell lines, two xenografts and eight primary tumours with array CGH to reveal the particular oncogenes associated with this cancer. This is the first genome wide survey of multiple oncogene amplifications involved in the development of NPC. Nonrandom gene amplifications were identified for the first time in NPC on MYCL1 in 1p34.3 and on TERC and PIK3CA at 3q26.3. Other high level amplified oncogenes included NRAS, RAF1, MYB, EGFR, FGF4, EMS1, and D17S167. Highest frequencies of gain of novel oncogenes were detected on MYCL1
Introduction
Nasopharyngeal carcinoma is a common cancer in the South East Asia region. It is the fourth most common cancer in Hong Kong males. Extensive molecular genetic studies including loss of heterozygosity studies and allelotyping analysis have been previously conducted to study the tumourigenesis of this cancer (1) (2) (3) (4) (5) (6) . Chromosomes 3p, 9p, 11q, 13q, and 14q were found to be frequently deleted in NPC. These chromosomal regions are suspected to be the location of the NPC related tumour suppressor genes (TSGs). RASSF1A gene (3p21) and p16 gene (9p21) have been identified to be two of the target TSGs (2, 7) . Besides defects of tumour suppressors, amplification of oncogenes are also involved in the development of cancers. In this study, our aim was to identify the oncogenes associated with NPC.
There are very few investigations performed to study the role of oncogene amplification in NPC. By fluorescence in situ hybridization (FISH), INT-2 amplification was shown in primary NPC samples (8) . The limitation of FISH analysis is that only one or a few candidate oncogenes can be examined in each experiment. Conventional cytogenetic analysis allows detection of multiple amplified chromosomal regions. However, aberrations may be lost or acquired during in vitro culturing. Studies of primary tumours can provide a more accurate pattern of genetic aberrations involved. The technique of comparative genomic hybridization (CGH) has been widely used to screen for multiple chromosomal aberrations including amplifications in various cancers (9) . Our previous CGH study of primary NPC revealed frequent gains on chromosomes 1q, 8, 12, 19 and 20 (10) . Amplified chromosomal regions identified by other CGH studies included 1q, 3q and 11q13 (11, 12) . CGH is a valuable technique for analysis of solid tumours from which good quality metaphases are extremely difficult to obtained for cytogenetic analysis. However, it has a limited mapping resolution. Genetic alterations at regions less than 20 Mb may not be detected (13) . While conventional CGH analysis reveals new amplified chromosomal regions, array CGH allows investigation of copy number changes in target oncogenes. Array CGH has been applied for identification of aberrant oncogenes involved in the development of human cancers (14, 15) . In the current study, we used a new technique of array based CGH to detect multiple oncogene amplifications in NPC. Commercial CGH microarray analysis system (Genosensor CGH, Vysis, Inc., Downers Grove, IL) was utilized. The CGH microarray template contained 58 target clone DNA (P1, PAC or BAC clones) representing most genomic regions which have been reported to be associated with tumour formation through amplification. Array CGH included a labeling step of normal control DNA and tumour DNA with nick translation. The tumour DNA and normal reference DNA were labeled with green fluorescent and red fluorescent tagged nucleotides respectively, and hybridized comparatively onto a CGH microarray template. Copy number changes of each of the 58 clones were measured and analyzed. As all of the amplicons were investigated simultaneously at one single experiment, array CGH can determine multiple amplified genes. To identify the common oncogenes involved in NPC carcinogenesis, a series of 15 NPC samples (5 cell lines, 2 xenografts and 8 primary tumours) were investigated.
Materials and methods
Cell lines and xenografts. Cell lines C666-1, HK-1, CNE-1, CNE-2 and HONE-1 (16) (17) (18) (19) were cultured with RPMI 1640 medium (Gibco BRL) supplemented with 10% fetal bovine serum (Gibco BRL), 1% L-glutamine (Gibco BRL) and 1% penicillin/streptomycin (Gibco BRL). Cultures at 70-80% confluence were harvested. The cell pellets were stored at -80˚C until DNA extraction. Two NPC xenografts xeno-2117 and xeno-NPC8 were included in this study. After removal of xenografts from nude mice, the tissues were snap-frozen and stored at -80˚C. Cell lines C666-1, HONE-1, CNE-2 and the two xenografts are undifferentiated tumours. Cell lines HK-1 and CNE-1 are well differentiated NPC.
Patients. All of the 8 NPC biopsies were obtained from patients with informed consent prior to treatment at Department of Clinical Oncology, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong. They were part of the cases which have been studied in our previous high resolution allelotyping analysis and CGH study (6, 10) . A small portion of the tissues were fixed in 10% buffered formalin for paraffin-embedding. The rest of the biopsies were embedded in OCT compound and stored at -80˚C, until retrieval for DNA extraction. All of the biopsies were histopathologically proven to be undifferentiated NPC (WHO type III, stage II or stage III) according to the WHO (1978) classification. The biopsies were histologically examined and shown to contain at least 70% of tumour cells. For cases with high percentages of normal lymphoid infiltration, either laser captured microdissection or manual microdissection were performed. As a result, a more pure and enriched population of tumour cells were obtained.
DNA extraction. High molecular weight DNA was extracted from the 15 NPC samples using conventional phenolchloroform method (20) . The tissues and cell pellets were firstly digested overnight in STE (saline tris-EDTA) solution containing 0.5% SDS and 0.2 mg/ml proteinase K (Sigma, St. Louis, MO) at 55˚C with shaking. After overnight incubation, phenol/chloroform extraction was performed to denature and remove protein content. In brief, the solution was mixed with phenol/chloroform/isoamylalcohol (25:24:1 in volume) solution (Amresco, Solon, OH) for 10 min and centrifuges at 4000 rpm at 4˚C for 20 min. The upper aqueous layer was collected, precipitated with 1/10 volume 3 M sodium acetate (pH 5.2) and 2.2 volumes cold absolute ethanol, then kept at -20˚C for at least one hour. After centrifugation at 4000 rpm for 20 min, the DNA pellet was washed with cold 70% ethanol. Thereafter, the pelleted DNA was air dried and dissolved in TE (tris-EDTA) solution (pH 7.5). The remaining RNA in the DNA solution was digested with 0.1 mg/ml DNAse-free RNAse A (Sigma, St. Louis, MO) at 37˚C for 2 hours, followed with proteinase K treatment at 55˚C for one hour. A second phenol-chloroform extraction was performed as described above. After air-drying in room temperature, the DNA pellet was dissolved in distilled water and kept at -20˚C for storage. Reference DNA was prepared from peripheral blood of normal healthy individuals.
Array based comparative genomic hybridization CGH (array CGH).
The array CGH protocols were performed as described previously (21) . DNA labeling was conducted with nick translation according to the manufacturer's protocol (Vysis, Downers Grove, IL). DNA of the tumour samples were labeled with Alexa-488 (green, Molecular Probes, Eugene), whereas normal reference DNA was labeled with Alexa-594 (red, Molecular Probes, Eugene). The labeled DNA should be less than 300 bp. 500-700 ng each of the labeled tumour DNA and reference DNA were mixed with microarray hybridization buffer which contained 50% formamide, 10% dextran sulfate and high concentration of Cot-1 DNA (Vysis, Downers Grove, IL). The probe mixture was denatured at 80˚C for 10 min and incubated at 37˚C for 1-2 hours before applied onto the AmpliOnc I microarray template (Vysis, Downers Grove, IL). Detail list of the amplicons can be obtained from http://www.vysis.com. Each of the 58 oncogenes was represented by 3 target spots. DNA clones of the desired target sequences were arrayed in target spots of approximately 100-250 µm diameter. Hybridization was carried at 37˚C incubator overnight. Thereafter, the microarrays were washed three times with 50% formamide/2X SSC at 40˚C for 10 min each. This was followed by four washes with 1X SSC at room temperature for 5 min each. The microarrays were left to air-dry in dark. Target spots were counter-stained with a blue fluorophore which included in the DAPI IV mounting solution (Vysis, Downers Grove, IL).
Fluorescent images of the green, red and blue fluorophore were captured with the GenoSensor Reader System (Vysis, Downers Grove, IL). The system contains a large-field multicolor fluorescence imaging system which captured an image of the hybridized chip in 3 color planes: green, red and blue. Target spots were automatically identified and analyzed by the software. The most representative ratio of the modal DNA copy number of the sample DNA was calculated by analyzing the set of green to red ratios on all the targets. For each target, the normalized ratio, relative to the modal DNA copy number was calculated. This normalized ratio of target indicated the degree of gain or loss of copy number when compared with the sample's modal copy number.
Results
The limits for measuring deviations was defined as described in our previous array CGH study (21) . Five independent comparative hybridizations using test and reference DNA made from normal individuals were conducted to determine the variations in the green to red ratios of the oncogenes in normal control DNA. Fluorescence ratios on the targets were measured to establish the baseline for measuring deviations. The measured ratios were ranged from 0.81 to 1.19. Mean ratio and standard deviation of the normal array CGH were 1.0 and 0.09 respectively. The measured fluorescence ratio of the extra copy of AR gene (located at Xq11-q12) in hybridization of normal female and normal male individuals were ranged from 1.49 to 1.52. A value of the mean ratio plus two standard deviations (mean ± 2 SD for all 5X58 targets equals 290 measurements) was set as the cut-off level for the normal gene copy number. Ratios higher than 1.18 and lower than 0.82 were considered to have deviations. Green to red ratios greater than 1.82 (>2 mean ± 2 SD) indicated the presence of at least 2 extra copies of that gene and were considered to have amplifications. Moreover, two sets of self to self hybridizations were conducted to test the reproducibility of measurements. This was performed by hybridizing the same source of DNA to different microarrays (21) .
Array CGH analysis was performed on 15 NPC samples, including five NPC cell lines, two NPC xenografts and eight primary NPC cases. Results of array CGH analysis are illustrated in Fig. 1. Fig. 2a shows an example of array CGH image. Frequency of copy number gains on the 15 NPC samples ranged from 0 to 66.7%. Fluorescent ratios of the green to red-labeled DNA ranged from 0.4 to 3.73. According to normal controls, ratios higher than 1.18 were scored to have copy number gains, whereas ratios lower than 0.82 were counted to have losses. Gain of amplicons were detected on most of the genes except MET, HRAS, WNT1, GLI, MDM2, AKT1, FES, TOP2A, YES1, BCL23', BCL25', JUNB, STK15, PTPN1, and CBFA2. Incidence of gains and amplifications occur more frequently in NPC cell lines and xenografts, than in primary tumours (Table I ). NPC cell lines or xenografts demonstrated high level amplifications in nine amplicons (Fig. 1) . But only one out of the eight primary NPCs illustrated gene amplification on MYCL1 gene (Fig. 1) . Three NPC cell lines (C666-1, CNE-1 and HONE-1) showed amplification of the TERC gene located at 3q26.3. Amplification of MYCL1 (1p34.3) and PIK3CA (3q26.3) were both identified in two cases. Amplification of PIK3CA was found in xeno-NPC 8 and cell line C666-1, whereas amplifications of MYCL1 were identified in C666-1 and one primary NPC tumour. Other high level amplified oncogenes included NRAS (1p13.2), RAF1 (3p25), MYB (6q22), EGFR (7p12.1-12.3), FGF4 (11q13), EMS1 (11q13), and D17S167 (17q23) (Fig. 1) . Amplification of each of these genes was found in one out of the 15 (6.7%) investigated NPC samples. Highest frequencies of gains were detected on MYCL1 (66.7%), TERC (46.7%), ESR (46.7%), PIK3CA (40%), LAMC2 (33.3%), and CSE1L (33.3%) located on 1p34.3, 3q26.3, 6q25.1, 3q26.3, 1q25-31 , and 20q13 respectively ( Table I) . As in the case of gene amplifications, incidence of gains were more frequently detected in cell lines and xenografts, than in primary tumours (Table I) .
While loss of chromosome 14q was frequently deleted in NPC (4,6), array CGH detected AKT1 gene loss (located in 14q13) in 46.7% of the cases (xeno-NPC8, C666-1 and 5 primary tumours). Loss of AKT1 gene was more frequently detected in primary tumours than in NPC cell lines and xenografts. As illustrated in Table II , other genes that frequently had loss of one copy included NRAS (1p13.2), BCL2 (18q21.3), CCNE1 (19q13.1) and BCR (22q11.21). Similar to AKT1 gene, loss of NRAS gene was detected in 5 primary tumours only. Loss of the other four genes were more frequently detected in cell lines and xenografts, than in primary NPCs.
Cases with gains of multiple candidate oncogenes were further analyzed to determine the presence of genes coamplified in NPC. With ¯2 or Fisher's exact test (p<0.0001), no statistically significant correlation was demonstrated among the oncogenes illustrating gains due to the limited 
Discussion
Our previous molecular genetic studies have identified several genetic lesions on NPC. These include chromosomal deletions and inactivated TSGs (1-7). Gene amplification is a reflection of genetic instabilities in solid tumour cells. Activation of proto-oncogenes by amplification is proposed to play an important role in the development of many human solid tumours. Detection of a specific gene amplification in tumour cells can lead to the identification of cellular genes involved in growth control and tumourigenesis of cancers. Only a limited number of gene amplification analysis have been conducted in NPC. Hence, in addition to TSGs, we aim to identify candidate oncogenes associated with NPC tumourigenesis. Amplification of C-MYC, RAS, BCL-2, INT-2 and MDM2 genes have been studied in NPC (8, (22) (23) (24) . INT-2 is the only oncogene that was found to be frequently amplified in NPC samples (8) . In these studies, implication of only one candidate oncogene was investigated at a time. As a consequence, a genome wide survey of amplified genes appears to be important in the detection of multiple common oncogenes involved in NPC. In the present study, we have used the method of genomic microarray to simultaneously study copy number changes of 58 human oncogenes throughout the genome of NPC. This array based comparative genomic hybridization allows analysis of multiple oncogenes commonly amplified in various human cancers.
CGH reveals the new amplified chromosomal regions in the genome without prior information or use of specific probe sets. With these clues, higher density target clones of corresponding amplified regions can be constructed. This can explore candidate oncogenes and facilitate the discovery of unknown amplified genes involved in the carcinogenesis of one particular cancer. However, CGH has a limited mapping resolution. Small regions of genetic alterations are usually overlooked or uncounted. Regions with complex aberrations which contain both gain and loss of genetic materials may not be properly elucidated. As a complement to CGH, array based CGH is effective in targeting the particular oncogenes of the amplified regions identified by CGH analysis (14, 15, 21) . The reproducibility of array CGH was evidenced in the normal hybridizations and self to self hybridizations. Moreover, novel findings of our previous array CGH study was further confirmed with FISH analysis (21) .
Chromosome 3q26 was found to be amplified in NPC by previous CGH studies (8, 12) . In array CGH templates, two oncogenes (TERC and PIK3CA) were located in the 3q26 region. TERC was amplified in three tumours and PIK3CA was amplified in two samples. High incidence of gains were also detected on both of these genes in four other NPC samples. This indicated that these two oncogenes may be involved in the development of NPC. PIK3CA encodes the p110 · catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). PI3-kinasse mediated signaling was associated with cell proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signaling and oncogenic transformation (25, 26) . TERC (telomerase RNA component) gene encodes the human telomerase RNA component (27) . Table II . Incidence of losses of amplicons.
Total number of loss in 15 NPC samples 5 7 Table I . Incidence of gains and amplifications of amplicons. 
Telomerase is a specialized ribonucleoprotein polymerase containing an RNA with a short template element that directs the synthesis of telomeric repeats at chromosomes ends (28) . Telomerase activation is a critical step in cell immortalization. Continued telomerase activity may be required for the longterm growth of cancer cells. Telomerase activation was reported in NPC and detected in 85% of primary tumours and 100% of recurrent tumours (29) . All of the xenografted NPC tumours and in vitro NPC cell lines were strongly positive for telomerase activity. Amplification of TERC gene may contribute to the telomerase activation of this cancer. The over-representation of PIK3CA and TERC in NPC will be further investigated by quantitative RT-PCR analysis and in situ hybridization.
To confirm the results of current array CGH study, FISH analysis of the most frequently amplified gene was performed. Amplifications of TERC in the metaphase chromosomes of the three NPC cell lines CNE-1, CNE-2, and HONE-1 were confirmed with FISH analysis using BAC probes. The BAC DNA was a gift from Vysis, Downers Grove, IL. For the NPC cell line CNE-1, the green to red ratio of array CGH on TERC gene was detected to be 2.02. This indicated the presence of two extra copies of this gene. FISH analysis of this tetraploid cell line illustrated the presence of multiple signals of TERC gene in the metaphases. In Fig. 2b , five chromosomes showed signals of TERC genes, and another chromosome had multiple copies of this gene. The other two tetraploid cell lines (CNE-2 and HONE-1) also illustrated multiple copies (>8) of TERC gene on FISH analysis (data not shown). The relatively large amplified chromosomal regions detected in CGH studies usually indicated a lot of candidate genes, however, it is unable to precisely find the target oncogenes. With array CGH, the involved genes can be clearly shown. As in the case of 3q26 amplification in cell line CNE-1, the candidate oncogene amplified in this sample was demonstrated to be TERC (green to red ration = 2.02) only, but not the adjacent PIK3CA gene (green to red ration = 0.99).
Amplification of 1p34.3 located MYCL1 (V-MYC avian myelocytomatosis viral oncogene homolog 1, lung carcinomaderived) gene was found in two investigated samples. This is also the oncogene that was most frequently gained in our series of NPC samples (Fig. 1) . In addition to the two cases of amplification, eight more samples illustrated gain of an extra copy of this gene. This is the first report demonstrating high frequency of MYCL1 gene in NPC. MYCL1 gene was cloned from DNA of small-cell lung cancer. It shares homology to a small region of both MYC and NMYC genes (30) . Correlation was reported between RFLP alleles of the MYCL gene and the occurrence of metastasis of lung cancer to lymph nodes and other organs (31) . ESR (estrogen receptor) gene is another newly identified oncogene that has been illustrated to have high frequency (47.7%) of gains in our array CGH analysis. ESR gene is located on 6q25.1. Gain of one extra copy of ESR gene was detected on four NPC cell lines and three primary NPC samples. ESR is a ligandactivated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription (32) . Presence of estrogen receptor was suggested to be able to identify those breast cancer patients with a lower risk of relapse and better overall survival. Measurement of ESR has become a standard assay in the clinical management of breast cancer (33) . The role of MYCL1 gene and ESR gene in NPC remained to be further elucidated.
Gain of the long arm of chromosome 1 and 20 were frequently identified in our previous CGH study (10) . In the present study, LAMC2 gene (1q25-31) and CSE1L gene (20q13) were both identified in five cases (33%) of the NPC samples. For chromosome 20q13, the microarray template included five candidate oncogenes (STK15, CSE1L, MYBL2, PTPN1 and ZNF217). Frequent copy number gains were demonstrated in CSE1L gene, while none or lower incidence of gains were detected on STK15, MYBL2, PTPN1 and ZNF217. This illustrated that array CGH is effective in searching the target oncogene(s) located in regions with several candidate genes. Our findings suggested that CSE1L may be the NPC associated target oncogene located on 20q13.
Chromosome 11q13 is one of the regions reported to be amplified on NPCs (8, 12) . Amplification of 11q13 located INT-2 gene was detected in 75% of NPC samples (8) . INT-2 gene was not covered in our current version of micro-array chips. The microarray template contained five other 11q13 located candidate oncogenes including CCND1, FGF4, EMS1, GARP and PAK1. However, amplifications were found in only one case of FGF4 and EMS1. Copy number gains were also rarely detected on these genes. These findings suggested that the target oncogene(s) may be INT-2 or other genes adjacent to this locus. Further detailed FISH mapping will be required to locate the target oncogenes. Chromosomes 8 and 12 were identified to have high incidence of gains in CGH analysis of NPC (8, 10, 12) . Gains of the ten clones (four clones on chromosome 8, six clones on chromosome 12) located on these two chromosomes were found in only three and six NPC tumours respectively (Fig. 1) . Hence, the target oncogenes cannot be confirmed in this study.
In conclusion, array CGH allows rapid detection of copy number changes of target oncogenes. By this genome wide detection assay, alterations of multiple amplified genes can be discovered in a single experiment. Array CGH can help to identify key genetic events to improve our understanding of the molecular basis of NPC. With the development of a higher resolution array template which encompasses more clones of candidate oncogenes and tumour suppressor genes, it may reveal even more complex events related to the development of this cancer.
